AG-012986

• Description:

  AG-012986 is a multitargeted CDK inhibitor. AG-012986 is active against CDK1/2/4/6/5/9, with Kis of 9.2 nM (CDK4/cyclin), 94 nM (CDK2/cyclin A), and 44 nM (CDK1/cyclin B), IC50s of 4 nM (CDK9/cyclin T) and 22 nM (CDK5/p35) . AG-012986 has antiproliferative activities against cancer cells. AG-012986 induces cell cycle arrest, and apoptosis[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; CDK

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.78

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C(C=C1)NC2=NC(N)=C(S2)C(C3=C(C=CC=C3F)F)=O)N[C@@H](CN(C)C)C

• Molecular Formula:

  C22H23F2N5O2S

• Molecular Weight:

  459.51

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Zhang C, et al. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Mol Cancer Ther. 2008 Apr;7 (4) :818-28.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK1; CDK2; CDK4; CDK5; CDK9

• CAS Number:

  [486414-35-1]